·¬ΗΡΚΣΖ΅

Meeting Coverage

ESMO

European Society for Medical Oncology

Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC

Follow-up results from phase II study show 12-month EFS rate of 89% in stage II-IV disease

ESMO over a photo of IFEMA Madrid in Spain.

Latest ESMO Meeting Coverage

Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC

Time to radiographic progression doubled with 177Lu-PSMA-617

October 25, 2023
New Options Challenge Standard Treatments in EGFR-Mutant NSCLC

Amivantamab-based regimens improved oncologic outcomes, but with more side effects

October 25, 2023
ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer

Adjuvant alectinib reduces disease-free survival hazard by 76%

October 24, 2023
Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers

Still some unanswered questions about benefit over other drug regimens, expert says

October 24, 2023
Randomized Trial Backs HIF-2a Inhibition in Advanced RCC

After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus

October 24, 2023
More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancer

PFS doubled and OS improved, driven by mismatch repair-deficient disease

October 23, 2023
Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer

Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy

October 23, 2023
Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer

Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care

October 23, 2023
New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions

Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses

October 23, 2023
'Practice-Changing' Data in Locally Advanced Cervical Cancer

Strategies involving immunotherapy, induction chemo move the needle for first time in decades

October 23, 2023
RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC

Two randomized studies demonstrate significantly improved PFS against standard regimens

October 22, 2023
Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer

Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy

October 22, 2023
Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond

Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation

October 22, 2023
Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer

Durvalumab plus olaparib, or alone, paired with chemo boosts PFS in DUO-E trial

October 21, 2023